Author

T. D. Laajala

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Approach:benchmark study· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Approach:deep learning· 1

Frequent Co-Authors

J. Westermarck· 2 shared A. D. Sahu· 1 shared A. Goodspeed· 1 shared A. Jean· 1 shared A. N. Cvrljevic· 1 shared A. Padzik· 1 shared A. Ristimaki· 1 shared A. S. Halkola· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Westermarck

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

M. Mason, O. Lapuente-Santana, A. S. Halkola, W. Wang, R. Mall, X. Xiao, J. Kaufman, J. Fu, J. Pfeil, J. Banerjee, V. Chung, H. Chang, S. D. Chasalow, H. Y. Lin, R. Chai, , B. G. Vincent

The paper evaluates predictive models for immune checkpoint inhibitor outcomes in NSCLC using clinical trial data from two RCTs, finding that models combining PD-L1, TMB, and immune signatures outperform single biomarkers.

Journal of Translational Medicine · Feb 21, 2024Peer-reviewedCancer Biology

Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis

M. Momeny, M. Tienhaara, D. Chakroborty, M. Sharma, R. Varjus, J. Merisaari, A. Padzik, A. Vogt, I. Paatero, K. Kurppa, K. Elenius, T. D. Laajala, J. Westermarck

This study identifies DUSP6 as a driver of HER2 inhibitor tolerance through the Neuregulin/HER3 axis by analyzing the transcriptional changes during the DTP-DTEP transition in HER2+ breast cancer cells.

bioRxiv · Jun 14, 2023 · PreprintCancer Biology

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

A. N. Cvrljevic, U. Butt, K. Huhtinen, T. Gronroos, C. Bockelman, H. Lassus, K. Kaipio, A. Ristimaki, T. Arsiola, T. D. Laajala, D. Connolly, O. Carpen, J. Pouwels, J. Westermarck

The paper identifies ovarian cancers with low CIP2A expression as a subtype sensitive to APR-246, a ROS-inducing compound, and shows CIP2A's role in modulating NF-kB activity and drug response.

bioRxiv · Mar 31, 2021Cancer Biology

NPEPPS is a novel and druggable driver of platinum resistance

R. T. Jones, M. Scholtes, A. Goodspeed, M. M. Akbarzadeh, S. Mohapatra, L. E. Feldman, H. Vekony, A. Jean, C. B. Tilton, M. V. Orman, S. Romal, C. Deiter, T. W. Kan, N. Xander, S. Araki, , J. C. Costello

This study identifies NPEPPS as a driver of cisplatin resistance in bladder cancer and shows its inhibition can enhance cisplatin efficacy in preclinical models.

bioRxiv · Mar 4, 2021 · PreprintCancer Biology